Login to Your Account



Pharnext inks three-part pact with China's Tasly

By Nuala Moran
Staff Writer

Wednesday, May 10, 2017

LONDON – Pharnext SA and Tasly Pharmaceutical Co. Ltd. signed a three-part agreement, which will see the Chinese pharma invest up to $44 million in a combination of equity, a joint venture, and the clinical development of  PXT-3003 in China.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription